Last reviewed · How we verify
Risk of low dose aspirin discontinuation — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Risk of low dose aspirin discontinuation (Risk of low dose aspirin discontinuation) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Risk of low dose aspirin discontinuation TARGET | Risk of low dose aspirin discontinuation | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Risk of low dose aspirin discontinuation CI watch — RSS
- Risk of low dose aspirin discontinuation CI watch — Atom
- Risk of low dose aspirin discontinuation CI watch — JSON
- Risk of low dose aspirin discontinuation alone — RSS
Cite this brief
Drug Landscape (2026). Risk of low dose aspirin discontinuation — Competitive Intelligence Brief. https://druglandscape.com/ci/risk-of-low-dose-aspirin-discontinuation. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab